See story on Pretzel, a pet dog with glioma successfully treated with PAC-1.

Clinical trials on companion animals diagnosed with cancer have brought new hope to their owners—and new data for a cutting-edge cancer drug being developed by scientists at Illinois.

By Mary Timmins

On the day we meet Pretzel, the weather is chilly and clear in Hammond, Ind., where she lives with her owners, Donna and Dave Gescheidler. Their living room décor anticipates Christmas, less than two weeks away, lively with greenery and patient little buildings and dancing figurines. But the best present of the season has already arrived. A visit to the clinic yesterday affirmed that the health of the little dachshund, a purebred red standard, continues stable—despite the tumor in her brain.

Read the rest of the Alumni article here.

A Phase 1b clinical trial of PAC-1 for glioblastoma patients has begun

A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib trial will determine if the experimental drug PAC-1 can be used safely in combination with a standard brain-cancer chemotherapy drug, temozolomide.

Read the rest of the Illinois News Bureau story here.

Watch the WCIA news story here.

Hergenrother Lab
261 Roger Adams Lab
600 S. Mathews Avenue
Urbana, IL 61802
Email: hergenro@illinois.edu